Liminal Biosciences Inc

NASDAQ:LMNL   2:45:55 PM EDT
4.08
-0.16 (-3.77%)
Products

Liminal Biosciences Announces FDA Approval For Its Biologics License Application For Ryplazim (Plasminogen, Human-Tvmh)

Published: 06/04/2021 19:39 GMT
Liminal Biosciences Inc (LMNL) - Liminal Biosciences Announces FDA Approval for Its Biologics License Application for Ryplazim® (plasminogen, Human-tvmh).
Liminal Biosciences Inc - FDA Approved Ryplazim for Treatment of Patients With Plasminogen Deficiency Type 1 Through Unit Prometic Biotherapeutics.